Fischer Medical Ventures targets $100 crore revenue by FY25, plans NSE listing

Fischer Medical Ventures Ltd. announced strategic progress and product portfolio expansion, targeting 100 crore revenue by FY25 and a listing on the NSE. The company, an accredited made-in-India MRI manufacturer, detailed its journey, including FDA/CE approvals for PICA (2011) and EMMA (2019) MRIs, and its expansion into R&D and manufacturing with all technology and distribution rights in India, MENA, and SEA by 2021. In 2024, it initiated an RTO onto BSE and obtained CDSCO approval for indigenously manufacturing MRIs.

The company highlighted a comprehensive range of MRI and CT scan devices, including the PICA low-res MRI and advanced CT 124 and 128 (with cardiac) models. Key competitive advantages include being the first and only to produce a 1.5T superconductor MRI system in India and a neonatal MRI system. Its facility in the Andhra Pradesh Medtech Zone ("AMTZ") positions it favorably for nationwide government orders, leveraging India's "local first and foreign next" procurement policy.

Fischer Medical Ventures also introduced new E-Health Access Points (eHAP) for decentralized health screening, offering instant health reports, AI-powered personalized meal plans, and tele-consultation. These innovations, coupled with strategic projects like the Edtech Project for health awareness and the FlynnCare 4T4TB initiative for tuberculosis management, aim to significantly reduce morbidity and deaths caused by non-communicable diseases. The company confirmed its health kiosks are CDSCO certified and all vendors are ISO certified.